KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.

Rocío Montejano, Fernando de la Calle-Prieto, María Velasco, Carlos Guijarro, Javier Queiruga-Parada, María Jiménez-González, Patricia González-Ruano, Patricia Martínez, Ane Josune Goikoetxea, Marta Ibarrola, Marianela Ciudad, Ángela Gutiérrez, Miguel Torralba, Ana Díaz-Brasero, Pablo Ryan, Cristina Marcelo, Cristina Díez, Sofía Ibarra, Esperanza Merino, Vicente Estrada, Javier Marcos, María Novella, María A Rivera, Manuel Ruiz-Muñoz, Marta de Miguel, Llanos Soler, Mikel Del Álamo, Santiago Moreno, Antonio J Carcas, Alberto M Borobia, José R Arribas, PANCOVID Study Group

Clin Infect Dis 76(3) e116-e125

PMID35906838
PMCIDPMC9384601
DOI10.1093/cid/ciac628
发表日期2022-07-30
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: This study was designed to evaluate if patients with high risk for severe coronavirus disease 2019 (COVID-19) would benefit from treatment with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) followed by baricitinib in case of hypoxemia and systemic inflammation. METHODS: PANCOVID is an open-label, double-randomized, phase 3 pragmatic clinical trial including adults with symptomatic COVID-19 with ≥2 comorbidities or aged ≥60 years and was conducted between 10 October 2020 and 23 September 2021. In the first randomization, patients received TDF/FTC or no TDF/FTC. In the second randomization, patients with room air oxygen saturation <95% and at least 1 increased inflammatory biomarker received baricitinib plus dexamethasone or dexamethasone alone. The primary endpoint was 28-day mortality. Main secondary endpoint was 28-day disease progression or critical care unit admission or mortality. The trial was stopped before reaching planned sample size due to the decrease in the number of cases and a mortality rate substantially lower than expected. RESULTS: Of the 355 included participants, 97% were hospitalized at baseline. Overall, 28-day mortality was 3.1%. The 28-day mortality relative risk (RR) for participants treated with TDF/FTC was 1.76 (95% confidence interval [CI], .52-5.91; P = .379); it was 0.42 (95% CI, .11-1.59; P = .201) for those treated with baricitinib. The 28-day RR for the main secondary combined endpoint for participants treated with TDF/FTC was 0.95 (95% CI, .66-1.40; P = .774); it was 0.90 (95% CI, .61-1.33; P = .687) for those treated with baricitinib. CONCLUSIONS: Our results do not suggest a beneficial effect of TDF/FTC; nevertheless, they are compatible with the beneficial effect of baricitinib already established by other clinical trials. CLINICAL TRIALS REGISTRATION: EudraCT: 2020-001156-18.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。